Modeled obesity-linked onset variability for sildenafil is a PK→PD construct describing how absorption rate, absorption timing, solubility, gastric emptying, distribution loading, distribution geometry, clearance geometry, and dose-scaling geometry shape rising-phase behavior across obesity-modeled parameter sets. “Onset variability” refers strictly to modeled PK→PD behavior, not real-world variability. Absorption rate determines rising-phase steepness, absorption timing determines temporal alignment, solubility determines dissolution-driven availability, and modeled gastric emptying determines input arrival. Distribution loading determines early central availability, distribution geometry determines compartmental spread, and clearance geometry determines removal dynamics. Dose-scaling geometry determines how modeled input is represented relative to reference trajectories. PD interpretation then defines onset-variability geometry: threshold placement establishes the onset boundary, binding sensitivity transforms concentration differences, coupling geometry shapes downstream transitions, and PD noise bands add interpretation width. Together, these parameters generate a modeled geometry for how an obesity-linked PK trajectory approaches a PD threshold, without asserting any real-world onset timing or outcome. Link to onset variability comparison.
Modeled obesity-linked absorption geometry for sildenafil describes the rising-phase shape of a concentration-time trajectory, rather than real-world absorption. Absorption rate determines rising-phase steepness, absorption timing determines temporal alignment, solubility determines dissolution-driven availability, and modeled gastric emptying shifts the represented arrival of absorbed input. Distribution loading determines early central-compartment concentration, while distribution geometry determines how absorbed material is represented across compartments. Redistribution timing can reshape the transition between early and later compartments, and clearance geometry determines concurrent removal. First-pass metabolism and CYP3A4 metabolism geometry modify the modeled amount reaching systemic circulation, while bioavailability changes the amplitude of that input. Dose-scaling geometry determines how these relationships change across modeled dose trajectories, and concentration-dependent clearance can alter curvature across the concentration-time path. The resulting PK curve supplies the input geometry that PD parameters subsequently transform into a modeled onset coordinate, without implying real-world absorption timing. Link to absorption rate.
PD geometry determines how modeled obesity-linked sildenafil PK differences are translated into an interpretation coordinate. Threshold placement establishes where each modeled concentration trajectory intersects the defined PD boundary, so identical PK shifts can produce different modeled onset separations when the threshold occupies a different position. Binding sensitivity determines how concentration differences are transformed into modeled binding differences; greater sensitivity can expand separation, whereas lower sensitivity can compress it. Coupling geometry determines how binding is mapped into a downstream PD signal, with shallow slopes broadening transitions and steep slopes compressing them. PD noise bands add a defined interpretation interval around the modeled signal. Because obesity-linked parameter sets can vary in absorption rate, solubility, gastric emptying, distribution loading, distribution geometry, bioavailability, Tmax geometry, and Cmax geometry, PD mapping can expand or compress modeled onset-variability and absorption differences. These effects remain model geometry rather than claims about real-world effectiveness, onset, or patient outcomes. Link to peak variability comparison.
The PK trajectory used for obesity-linked onset-variability modeling is generated by interacting absorption rate, absorption timing, solubility, modeled gastric emptying, distribution loading, distribution geometry, redistribution timing, clearance geometry, first-pass metabolism, CYP3A4 metabolism geometry, bioavailability, and dose-scaling geometry. Absorption rate controls the slope of the rising phase, while absorption timing positions that phase along the time axis. Solubility controls dissolution-driven availability, and modeled gastric emptying determines when input enters the absorptive process. Distribution loading shapes early central concentration, whereas distribution geometry and redistribution timing determine compartmental movement. Clearance geometry removes drug concurrently with absorption and distribution, altering curve curvature and persistence. First-pass metabolism and CYP3A4 geometry modify systemic input, while bioavailability scales the amount represented as available. Dose-scaling geometry changes how these relationships are represented across modeled dose trajectories. Tmax and Cmax geometry then summarize timing and amplitude features of the resulting curve, providing the PK coordinates that can be mapped into a modeled onset construct. Link to absorption rate.
Across obesity-modeled parameter sets, changes in absorption, distribution, metabolism, and elimination parameters can generate distinct concentration-time geometries without establishing that any particular geometry occurs in real-world obesity. A faster modeled absorption rate can produce a steeper rising phase, while altered absorption timing or modeled gastric emptying can shift the position of that rise. Changes in solubility or bioavailability can modify amplitude, whereas distribution loading, compartmental geometry, and redistribution timing can alter early concentration and subsequent curvature. Clearance geometry, first-pass metabolism, and CYP3A4 geometry can further reshape the trajectory by changing concurrent removal or systemic input. These differences can produce modeled absorption windows with different widths and modeled Tmax and Cmax coordinates. The resulting onset-variability construct therefore represents a comparison among parameterized trajectories rather than an observed population pattern. The geometry describes how specified PK inputs interact mathematically to generate different rising-phase profiles within the model. Link to distribution speed.
| PK Domain | Obesity Interaction | Link |
|---|---|---|
| Absorption Rate | Steeper or flatter rising phase. | absorption rate |
| Gastric Emptying | Shifted input arrival. | food effect speed |
| Distribution Geometry | Compartmental spread. | distribution speed |
Threshold placement establishes the concentration or signal boundary used to assign a modeled onset coordinate. When obesity-linked PK parameter sets generate different rising-phase trajectories, moving the threshold within the modeled concentration-time geometry can change where each trajectory is interpreted as crossing the boundary. A threshold positioned near a steep portion of a curve can create greater separation between trajectories than a threshold positioned within a flatter region. The same PK trajectory can therefore produce different modeled onset coordinates when threshold placement changes, while the underlying concentration-time profile remains unchanged. In this framework, threshold placement does not represent a measured clinical onset boundary. It is a defined mathematical coordinate used to translate PK geometry into PD interpretation. Binding sensitivity, coupling geometry, and PD noise bands can subsequently modify the width and separation of the resulting interpretation region. The complete construct therefore links absorption timing and rising-phase geometry to a modeled onset coordinate without assigning real-world timing. Link to pd speed.
Binding sensitivity, coupling geometry, and PD noise bands determine how strongly modeled PK differences are represented after the concentration trajectory reaches the PD layer. Binding sensitivity controls the transformation from concentration differences to modeled binding differences. Coupling geometry then maps those binding differences into a downstream PD signal, with its slope and curvature determining whether trajectories become more separated or more compressed. PD noise bands add an explicit interpretation interval around that signal, allowing the modeled boundary region to remain narrow or broadened according to the defined parameterization. Consequently, two obesity-linked PK trajectories with similar Cmax or Tmax differences can generate different modeled onset-variability patterns when the PD mapping changes. Conversely, different PK trajectories can appear closer together when binding and coupling geometry compress their separation. These are transformations of mathematical coordinates rather than observations of patient responses. The PD layer therefore acts as a geometry-mapping stage between PK trajectory differences and modeled onset interpretation. Link to pk speed.
| PD Domain | Obesity PD Interaction | Link |
|---|---|---|
| Threshold Placement | Earlier/later onset coordinate. | onset time |
| Binding Sensitivity | Amplification/compression. | onset variability comparison |
| Coupling Geometry | Slope-driven shaping. | peak variability comparison |
Modeled obesity-linked onset variability and absorption differences arise from the combined geometry of absorption, distribution, metabolism, elimination, and PD interpretation. Absorption rate determines the steepness of the modeled rising phase, while absorption timing and modeled gastric emptying determine where that phase is positioned. Solubility and bioavailability shape represented systemic input, while distribution loading, distribution geometry, and redistribution timing shape early and subsequent concentration patterns. Clearance geometry, first-pass metabolism, and CYP3A4 geometry alter the trajectory by changing removal or systemic availability. Dose-scaling geometry determines how these relationships are represented across modeled dose levels. Tmax and Cmax geometry summarize timing and amplitude features of each trajectory. PD threshold placement then defines the modeled onset coordinate, while binding sensitivity, coupling geometry, and PD noise bands transform PK differences into an interpretation band. Thus, the construct describes mathematical trajectory differences, not observed onset variability, absorption timing, effectiveness, or patient outcomes.
The main PK mechanisms are represented as parameterized components of the concentration-time model. Absorption rate controls the slope of the input phase, while absorption timing controls its temporal position. Solubility influences dissolution-driven availability, and modeled gastric emptying determines the represented arrival of material to the absorptive process. Bioavailability determines the fraction represented as systemically available after input and first-pass processes. Distribution loading controls early central-compartment representation, while distribution geometry and redistribution timing describe movement among modeled compartments. Clearance geometry determines how concentration is removed over time, and first-pass metabolism plus CYP3A4 metabolism geometry modify systemic input. Dose-scaling geometry changes how these parameters are represented across modeled dose trajectories. Tmax and Cmax geometry then provide summary coordinates for timing and amplitude. Together, these mechanisms create modeled absorption and rising-phase shapes that can differ across obesity-parameterized simulations, without asserting that those shapes correspond to actual human absorption timing.
PD mechanisms shape the interpretation of an obesity-linked PK trajectory after the concentration-time geometry has been generated. Threshold placement defines the concentration or signal boundary used to assign a modeled onset coordinate. Binding sensitivity controls how changes in modeled concentration are translated into changes in binding or receptor-proximal representation. Coupling geometry determines how that intermediate quantity is transformed into a downstream PD signal, including the slope and curvature of the mapping. PD noise bands represent an explicit interval around the modeled signal and therefore can widen or narrow the interpretation region. These parameters can amplify, compress, or shift the apparent separation between two PK trajectories even when their underlying concentration differences remain unchanged. The resulting geometry is therefore a property of the specified PK→PD mapping. It does not establish a real-world onset time, effectiveness level, safety profile, or patient outcome; it only describes how defined model parameters transform one coordinate system into another.
Modeled obesity-linked trajectories differ because each parameter set can assign different values or functional forms to absorption, distribution, metabolism, elimination, and dose-scaling components. A change in absorption rate modifies rising-phase steepness, whereas a change in absorption timing or modeled gastric emptying shifts the input along the time axis. Solubility and bioavailability alter represented systemic input, while distribution loading, distribution geometry, and redistribution timing alter compartmental concentration patterns. First-pass metabolism and CYP3A4 geometry can change systemic availability, and clearance geometry can reshape the descending and overlapping portions of the trajectory. Concentration-dependent clearance can additionally introduce curvature that varies with concentration. The resulting Tmax and Cmax coordinates may therefore differ between parameter sets. These differences are mathematical consequences of the specified model structure and parameter values. They should be interpreted as modeled geometry rather than evidence that obesity produces a particular real-world absorption pattern, onset interval, effectiveness difference, or patient-level outcome.
PK→PD mapping explains modeled obesity-linked onset-variability by separating the generation of a concentration trajectory from the interpretation of that trajectory. PK parameters first determine input, distribution, metabolism, clearance, Tmax, Cmax, and the shape of the rising phase. The PD layer then places a threshold on that trajectory and applies binding sensitivity, coupling geometry, and noise bands. A small PK shift can therefore produce a larger modeled onset separation when the threshold lies on a steep portion of the trajectory-to-signal mapping. Conversely, a larger concentration difference can produce a smaller interpreted separation when coupling is shallow or the threshold position compresses the relevant region. The same logic applies to modeled absorption geometry because PD mapping can change how PK curve differences are represented without changing the underlying PK curve. This framework remains entirely mechanistic: it describes parameter-to-trajectory and trajectory-to-signal transformations, not observed absorption timing, clinical effectiveness, or patient outcomes.